^
Association details:
| Biomarker: | TLE3 expression |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Halaven (eribulin mesylate) (Microtubule inhibitor, CBP inhibitor, β-catenin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Identification of predictive markers of the therapeutic effect of eribulin chemotherapy for locally advanced or metastatic breast cancer
Excerpt:
A multivariate logistic regression analysis by Ki67 and TLE3 including 22 patients with TNBC also showed that a positive TLE3 expression significantly correlated with a better PFS (p = 0.037, Hazard ratio = 0.126, 95% CI = 0.018–0.885). Therefore, TLE3 expression in the tumor was identified to be an independent predictive marker of the therapeutic effect of eribulin chemotherapy among patients with TNBC lesions (Table 5).
DOI:
10.1186/s12885-017-3598-5
